Brief: Crescent Biopharma Announces FDA Clearance Of Ind Application For CR-002, A Pd-L1-Targeted Topoisomerase Inhibitor Adc, For The Treatment Of Solid Tumors
05/10/2026 12:38
BRIEF-Crescent Biopharma Announces FDA Clearance Of Ind Application For CR-002, A Pd-L1-Targeted Topoisomerase Inhibitor Adc, For The Treatment Of Solid Tumors Oct 5 (Reuters) - Crescent Biopharma, Inc. CBIO.O:
CRESCENT BIOPHARMA ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR CR-002, A PD-L1-TARGETED TOPOISOMERASE INHIBITOR ADC, FOR THE TREATMENT OF SOLID TUMORS
CRESCENT - INITIAL CLINICAL DATA FROM APOLLO TRIAL EXPECTED IN SECOND HALF OF 2027
CRESCENT - APOLLO PHASE 1/2 GLOBAL TRIAL FOR CR-002 TO INITIATE IN Q4 2026
Source text: ID:nGNXbyqqmK
Further company coverage: CBIO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Crescent Biopharma
See all newsBrief: Crescent Biopharma - Potential To Initiate First CR-001 Phase 3 Study In Early 2028
Brief: Crescent Biopharma Announces FDA Clearance Of Ind Application For CR-002, A Pd-L1-Targeted Topoisomerase Inhibitor Adc, For The Treatment Of Solid Tumors
Crescent Biopharma posts smaller-than-expected Q2 net loss
U.S. STOCKS ON THE MOVE-Cintas, Veradermics
Crescent Biopharma slips on $125 mln share offering